Groups of 70 male and 70 female Charles River CD (SpragueDawley-derived) rats were exposed whole body to styrene vapor at 0, 50, 200, 500, or 1000 ppm 6 h/day 5 days/week for 104 weeks. The rats were observed daily, body weights and food and water consumption were measured periodically, and a battery of hematologic and clinical pathology examinations was conducted at weeks 13, 26, 52, 78, and 104. Nine or 10 rats per sex per group were necropsied after 52 weeks of exposure and the remaining survivors were necropsied after 104 weeks. Control and highexposure rats received a complete histopathologic examination, while target organs, gross lesions, and all masses were examined in the lower exposure groups. Styrene had no effect on survival in males, but females exposed to 500 or 1000 ppm had a dose-related increase in survival. Levels of styrene in the blood at the end of a 6-h exposure during week 95 were proportional to exposure concentration. Levels of styrene oxide in the blood of rats exposed to 200 ppm or greater styrene were proportional to styrene exposure concentration. There were no changes of toxicologic significance in hematology, clinical chemistry, urinalysis, or organ weights. Males exposed to 500 or 1000 ppm gained less weight than the controls during the first year and maintained the difference during the second year. Females exposed to 200, 500, or 1000 ppm gained less weight during the first year; those exposed to 500 or 1000 ppm continued to gain less during months 13-18. Styrene-related nonneoplastic histopathologic changes were confined to the olfactory epithelium of the nasal mucosa. There was no evidence that styrene exposure caused treatment-related increases of any tumor type in males or females or in the number of tumor-bearing rats in the exposed groups compared to controls. In females, there were treatment-related decreases in pituitary adenomas and mammary adenocarcinomas. Based on an overall evaluation of eight oncogenicity studies, there is clear evidence that styrene does not induce Cancer in rats.
Groups of 70 male and 70 female Charles River CD (SpragueDawley-derived) rats were exposed whole body to styrene vapor at 0, 50, 200, 500, or 1000 ppm 6 h/day 5 days/week for 104 weeks. The rats were observed daily, body weights and food and water consumption were measured periodically, and a battery of hematologic and clinical pathology examinations was conducted at weeks 13, 26, 52, 78, and 104. Nine or 10 rats per sex per group were necropsied after 52 weeks of exposure and the remaining survivors were necropsied after 104 weeks. Control and highexposure rats received a complete histopathologic examination, while target organs, gross lesions, and all masses were examined in the lower exposure groups. Styrene had no effect on survival in males, but females exposed to 500 or 1000 ppm had a dose-related increase in survival. Levels of styrene in the blood at the end of a 6-h exposure during week 95 were proportional to exposure concentration. Levels of styrene oxide in the blood of rats exposed to 200 ppm or greater styrene were proportional to styrene exposure concentration. There were no changes of toxicologic significance in hematology, clinical chemistry, urinalysis, or organ weights. Males exposed to 500 or 1000 ppm gained less weight than the controls during the first year and maintained the difference during the second year. Females exposed to 200, 500, or 1000 ppm gained less weight during the first year; those exposed to 500 or 1000 ppm continued to gain less during months 13-18. Styrene-related nonneoplastic histopathologic changes were confined to the olfactory epithelium of the nasal mucosa. There was no evidence that styrene exposure caused treatment-related increases of any tumor type in males or females or in the number of tumor-bearing rats in the exposed groups compared to controls. In females, there were treatment-related decreases in pituitary adenomas and mammary adenocarcinomas. Based on an overall evaluation of eight oncogenicity studies, there is clear evidence that styrene does not induce Cancer in rats. © 1998 Society of Toxicology.
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Styrene (ethenylbenzene, ) is a clear, colorless liquid with a characteristic pungent odor. In 1993, world-wide production capacity of styrene was 17.8 million tons (Miller et al., 1994) . Styrene is used in the production of many important commercial polymers including polystyrene, acrylonitrile-butadiene-styrene (ABS), styrene-acrylonitrile (SAN), styrene-butadiene (SB latex, SB rubber), and in resins used in the manufacture of numerous glass-reinforced plastic products (e.g., boats, tubs, and tanks). The greatest occupational exposures occur in the reinforced plastics industry. However, in all of the industrial uses of styrene, other chemicals are present in the workplace atmosphere; thus, an understanding of potential styrene toxicity in humans is complicated by the presence of these other chemicals.
Exposure (Miller et al., 1994) , toxicologic (McConnell and Swenberg, 1994; Phillips and Fanner, 1994; Scott and Preston, 1994) , metabolic (Sumner and Fennell, 1994) , and epidemiologic (Rebert and Hall, 1994; Coggon, 1994 ) data on styrene were recently reviewed. Several chronic toxicity/oncogenicity studies of styrene in rats were performed in the 1970s (Table  1) , but most are deficient for use in human health hazard assessments due to problems which included route of exposure, dose interval, small group sizes, intercurrent disease, exceeding the maximum tolerated dose, and minimal descriptions of the conduct and detailed results of the studies (McConnell and Swenberg, 1994) . Therefore, the Styrene Information and Research Center initiated state-of-the-art subchronic and chronic studies of styrene by the inhalation route.
The 13-week inhalation study of styrene in CD rats (Cruzan et al., 1997) identified 1000 ppm for 6 h/day 5 days/week as the predicted maximum tolerated dose in males and females based on increased water consumption and reduced body weight gain. In addition, lesions were seen in the nasal olfactory epithelium at exposure levels of 500, 1000, and 1500 ppm. Based on the behavior of the rats, these concentrations appeared to be irritating during exposure. This report describes the subsequent chronic toxicity/ oncogenicity study in rats. A companion chronic toxicity/ oncogenicity study in mice was initiated later than the rat study and will be reported separately. Beliles et al, 1985 Conti et al., 1988 Ponomarkov and Tomatis, 1978 NCI, 1979a NCI, 1979b Conti et al, 1988 Jersey et al, 1978 Conti et al, 1988 Conti et al, 1988 
MATERIALS AND METHODS
Test material Commercial styrene was supplied by Shell Chemicals UK Ltd. Each batch was analyzed for purity by gas chromatography/mass spectroscopy (GC/MS); the batches were typical of commercial styrene. Analyses of styrene aliquots taken at the start and finish of each drum showed styrene >99.5 to 99.7%, benzene <1 to 24 ppm, ethylbenzene 143 to 731 ppm, styrene dimer <1 to 6 ppm, styrene oxide <5 to 6 ppm, and tertiary butyl catechol (inhibitor) 5 to 15 ppm. Drums were stored at 4°C.
Exposure generation and analysis system. Styrene was metered from a sealed reservoir pressurized by nitrogen to drip onto a glass sinter; heated air (60°C) was passed through the glass sinter to vaporize styrene. The air temperature was kept at the minimum required for vaporization to minimize the formation of oxides, dimers, or polymers. The styrene-laden air was diluted with filtered conditioned air and introduced into the 2.43-m 3 stainless steel and glass whole body exposure chambers. Chamber environmental conditions, including styrene concentration, airflow, temperature, and humidity, were recorded every 30 min during each 6-h exposure period using an automated system. Analytical determination was by GC using styrene, styrene oxide, and styrene dimer standards for identification. Chamber air was analyzed monthly by GC for styrene oxide (limit of detection, 0.25 ppm) and styrene dimer (limit of detection, ~2 ppm). Nominal and analyzed chamber concentrations of styrene were calculated for each day. Rats were exposed for at least 104 weeks.
Animals and husbandry. Virus antibody-free CD (Sprague-Dawley) rats were received from Charles River Portage at approximately 4 weeks of age. Prior to study initiation, selected rats were sampled for hematologic (methods described below) and serologic investigations and macroscopic evaluation at necropsy. Serologic evaluation of sentinel rats was performed every 8 weeks throughout the study for possible rat viral and mycoplasma infections. The rats were housed five/cage in suspended stainless steel caging when not in the inhalation chambers. During exposures each animal was housed separately. Animal husbandry complied with the requirements of the UK Home Office Animals (Scientific Procedures) Act 1986. Animals were fed pelleted SDS Rat and Mouse Diet No. 1 (Special Diet Services, Witham, Essex, UK) ad libitum; tap water was provided ab libitum, except during exposures, from water bottles which were rinsed and filled daily and thoroughly cleaned periodically. Analysis of all batches of diet demonstrated them to be within nutritional requirements and to not have chemical or bacterial contamination that would interfere with the study. Drinking water was analyzed every 6 months and found to be within safe limits for selected chemical contaminants. Animals were housed in air-conditioned rooms with 12-h light/dark cycles.
Experimental design. During the acclimation period, rats were assigned to five groups of 70 males and 70 females by a stratified randomization according to body weight. Four groups of rats were exposed to styrene vapor 6 h/day for at least 104 weeks (520 exposures) at target concentrations of 50, 200, 500, or 1000 ppm (Groups 2, 3,4, and 5, respectively) in 2.43-m 3 inhalation chambers. The remaining group (Group 1) served as a control and were treated to the same inhalation chamber conditions, but were not exposed to styrene. Ten predesignated rats of each sex from each group were sacrificed after 52 weeks of exposure. The animals were individually observed for clinical signs at daily placement and removal from the inhalation chamber; group observations were made during exposures. Body weight was determined weekly for the first 13 weeks and every 4 weeks thereafter. Food consumption was measured weekly throughout the study. Overnight water consumption was measured daily during weeks 1, 4, 12, 25, 51, 77, and 103 . After dilation with a tropicamide ophthalmic solution, the eyes of all rats were examined using a Keeler indirect ophthalmoscope before exposures began and after 52 and 104 weeks of exposure.
Following an overnight fast, blood was obtained from the periorbital plexus of 10 males and 10 females from each group after 13, 26, 52, 78, and 104 weeks of exposure for hematology and clinical chemistry determinations. For the first three intervals, the rats sampled were those scheduled for termination after 52 weeks. Hematologic evaluation included packed cell volume, hemoglobin, erythrocyte (RBC) count, white blood cell (WBC) count, reticulocyte count, platelet count, and Thrombotest (Ortho ELT 1500). WBC differential count and RBC morphology were evaluated using Wright's stained blood smears. Clinical chemistry evaluation included creatine phosphokinase, sorbitol dehydrogenase, 5'-nucleotidase, phospholipid (Roche Cobas centrifugal analyzer), glucose, alanine aminotransferase, aspartate aminotransferase, total protein, albumin, globulin (by subtraction), urea nitrogen, alkaline phosphatase, total bilirubin, creatinine, sodium, potassium, calcium, inorganic phosphorus, chloride, and cholesterol (Hitachi 737 analyzer). Urine was collected overnight after weeks 13, 26, 52, 78, and 104 and analyzed for pH, volume, osmolality, color, appearance, and microscopic material. Dipsticks (Ames Co.) were used for semiquantitative analysis of total reducing substances, glucose, ketones, proteins, bile pigments, urobilinogen, and heme pigments. Protein, creatinine, and glucose were measured using a Roche Cobas centrifugal analyzer.
During week 95, blood was obtained from five males and five females of each group immediately at the end of the daily exposure of each animal. In the last few minutes of the 6-h exposure, the chamber door was opened slightly for the removal of each rat separately; blood was collected within 2 min of removal from exposure. The concentrations of styrene and styrene-7,8-oxide were determined in each sample by immediate extraction of blood into hexane and analysis of the hexane fraction by capillary gas chromatography based on the method of Kessler et al. (1990) .
Ten animals per sex per group (except 9 females each in the 0, 500, and 1000 ppm groups because of mortalities before week 52) were euthanized after 52 weeks by exsanguination under deep pentobarbitone anesthesia and necropsied. All surviving animals were euthanized by the same method during weeks 105-107. The following organs from each animal, except for those animals found dead, were dissected free and weighed: adrenal glands, brain, kidneys, liver, lungs, spleen, and ovaries/testes. Tissues were preserved in neutral-buffered formalin; eyes were preserved in Davidson's fixative. Lungs were inflated with neutral-buffered formalin before immersion in fixative. At necropsy, the nasal cavity was flushed with neutral-buffered formalin. The lower jaw was removed and the head was immersed in neutral-buffered formalin.
Following fixation, the head was decalcified in Kristensen's fluid (6 days) and the nasal cavity was sampled at 4 levels based on the description of Young (1981) . Tissues for histologic evaluation were routinely processed, embedded in paraffin wax, and 4-^.m sections were prepared, stained with H&E, and examined under the light microscope. The following tissues from the high exposure and control animals were examined: nasal passages, nasopharynx, larynx, trachea, lungs, aorta, heart, thymus, cervical and mandibular lymph nodes, spleen, liver, pancreas, kidneys, urinary bladder, uterus, cervix, ovaries, prostate, seminal vesicles, epididymides, testes, thyroid glands, parathyroid glands, adrenal glands, pituitary gland, salivary glands, skeletal muscle, esophagus, stomach, duodenum, jejunum, ileum, cecum, colon, rectum, mammary glands, skin, spinal cord, sciatic nerve, brain, femur, sternum/bone marrow, eyes, extraorbital lacrimal glands, and Harderian glands, as well as other macroscopically abnormal tissue including all masses. In addition to histopathologic examination of the control and high-exposure animals, histopathologic examination of the nasal passages, lungs, liver, kidneys, testes/ epididymides, and macroscopic abnormalities was performed on the animals of all lower exposure levels.
The study was conducted in accordance with Good Laboratory Practices (US EPA, 1989; UK HSE, 1989; EC Council, 1986; Japan MIT1, 1984; OECD, 1982) . Pathology observations were peer reviewed within the testing facility and by an independent pathologist (W.R.B.).
Statistics. Quantitative data were analyzed by Bartlett's (1937) test for homogeneity; if the data were heterogenic, a logarithmic transformation was performed to see if a more stable variance could be obtained. Data without significant heterogeneity were analyzed by one-way analysis of variance and Williams' test (1971 Williams' test ( , 1972 for dose response. The Kruskal-Wallis Wallis, 1952, 1953) analysis was performed for nonparametric data. For organ weight data, the final body weight was used as a covariate in the analysis of covariance.
Mortality was analyzed using the log ranks method (Mantel, 1966) . Tumor incidence was analyzed using methodology described by the International Agency for Research on Cancer (IARC, 1980) . Other pathologic data were analyzed using Fisher's (1973) exact test.
RESULTS

Exposure Conditions
Average analyzed concentrations (standard deviation) of styrene were 0, 50 (2.6), 202 (6.4), 501 (15.8), and 997 (36.0) ppm. These measured concentrations were within 1% of those intended; therefore, concentrations are referenced by target level in this publication. Nominal concentrations (the amount of styrene used daily divided by the daily chamber airflow) were 49, 194, 506, and 1019 ppm. No styrene oxide or styrene dimer was detected in any of the exposure chambers. Chamber airflow averaged 647, 644, 646, 647, and 646 liters/min for Groups 1-5 (0, 50, 200, 500, and 1000 ppm), respectively. Mean chamber temperature and humidity were 21.6, 21.4, 21.3, 21.0, and 20.3°C and 57, 56, 60, 67 , and 67% for Groups 1-5, respectively. Increased chamber humidity and slightly decreased chamber temperature were consistently observed with increasing exposure level and were attributed to the animals' reaction to styrene exposure.
Sentinel Animals
Serological analysis of blood samples obtained from the sentinel rats prior to study initiation, at 8-week intervals during the study, and from two rats per sex per group at the terminal sacrifice were all negative for the antibodies examined. There was no evidence of any infectious disease at any stage of this study.
Survival and Observations
During week 61, eight males in the 1000 ppm group and six males in the 500 ppm group received a massive dermal exposure of styrene due to a technical problem which resulted in liquid styrene dripping into the exposure chambers in a discrete location at the start of exposure. All died or were sacrificed within the next 2 weeks and were not included in the mortality or tumor analysis. Inhalation of styrene had no effect on survival of male rats (Table 2 ). There was a dose-related increase in survival of female rats (Table 2) exposed to 500 or 1000 ppm relative to control females.
There were no effects of styrene exposure on appearance or behavior of rats at exposure concentrations up to 1000 ppm except during exposures. Rats exposed to styrene at 500 and 1000 ppm exhibited signs indicative of its irritating properties: salivation with restlessness, which lasted up to 30 min after the start of each exposure, followed by hunched posture for the remainder of the exposure period. In general, effects were most evident on Mondays with a gradual diminution by Friday. Salivation, increased urination, and/or water loss through the respiratory system may have been sufficient to cause increased humidity and slightly lower temperature in the exposure chambers for Groups 4 and 5 (see above). This increased humidity was not seen if the chambers were operated with rats present without styrene exposure or styrene exposure without rats present, based on studies conducted during the weekend when styrene exposure of the test animals were not conducted (data not shown). When body weights were measured before and after a 6-h exposure period on Monday and on Friday of week 46, weight loss during exposure was increased in all exposure groups in males and at 1000 ppm in females. In addition, exposed rats consumed more water than controls in the first hour after exposure when measured during week 46. These findings are consistent with increased fluid loss during exposure.
Body Weight and Food and Water Consumption
Males exposed to 500 ppm and 1000 ppm styrene gained less weight than the controls (Fig. 1A) , primarily during the first year of the study and consumed less food during the first 26 weeks (data not shown). After 1 year males at 500 ppm had gained 10% less weight than controls and males at 1000 ppm had gained 17% less. During the next 6 months the weight " Based on 60 per sex per group designated for 24 months of study; does not include deaths in subgroups (10/sex/group) scheduled for sacrifice at 52 weeks. After week 61 Group 4 (500 ppm) survival of males based on 54 rats; Group 5 (1000 ppm) males based on 52 rats. Survival of females exposed to 500 or 1000 ppm significantly greater than control.
differences remained the same. Over the last 6 months the styrene-exposed males lost less weight than the controls; thus, the weight differences were less at the termination of the study. Males exposed to 50 ppm styrene gained more weight than the controls throughout the study; after 104 weeks they had gained 15% more.
Females exposed at 200, 500, or 1000 ppm gained significantly less weight than the controls during the first year ( Fig.  IB) : 10, 29, and 34% less, respectively. Those exposed to 500 or 1000 ppm continued to gain less weight through 78 weeks. From week 91 to the end of the study females exposed to 500 ppm weighed less than those exposed to 1000 ppm. Females exposed to 500 and 1000 ppm consumed -10% less food throughout the study than did the controls.
In males exposed to 500 or 1000 ppm, there was a doserelated increase in water consumption throughout the study (Table 3 ; 121 and 127% of control consumption). Similar increases in water consumption were evident in females exposed to 500 or 1000 ppm only during the first 6 months (Table  3) . Increased water consumption (112% of control consumption) was recorded in both males and females exposed to 200 ppm during the first month of the study. At week 39, visual observation of drinking behavior post exposure and overnight placement of hoppers beneath the water bottles did not find evidence of unusual spillage or other loss of water due to interference with the water bottles by the rats.
Hematology, Clinical Chemistry, Urinalysis, and Ophthalmology
There were no hematology or clinical chemistry differences between treated and control rats that were of toxicologic significance (data not shown). Minor elevation of serum phosphorus levels, noted inconsistently, may have been related to effects of styrene exposure on water balance.
Urine pH was decreased in a dose-related manner in rats exposed to 200, 500, or 1000 ppm (Table 3) ; this is presumed to be due to the excretion of increasing amounts of mandelic and phenylglyoxylic acids, the normal urinary excretion products of styrene metabolism. Increased osmolality may have been related to water balance.
Styrene and Styrene Oxide in Blood
Levels of styrene in blood at the end of a 6-h exposure during week 95 were proportional to exposure concentration (Table 4) . No styrene or styrene oxide was detected in the blood of control rats. Although styrene was found in the blood of rats exposed to 50 ppm, no styrene oxide was found (limit of detection 10 ng/ml). Levels of styrene oxide in the blood of rats exposed to 200 ppm or greater were proportional to the styrene exposure concentration, although the increase was to a much lesser extent than that for styrene.
Organ Weights
Using body weight as a covariate, there were no toxicologically significant differences in organ weights between treated and control rats at the interim or terminal sacrifices (data not shown). Because of the body weight differences, expected lower liver and kidney weights and increased relative brain and gonad weights were found.
Pathology
At the week 52 interim necropsy, no treatment-related macroscopic changes were observed in any tissue. At the terminal necropsy, it was observed that more male rats exposed to 500 and 1000 ppm had testicular masses than the other groups. In addition, at the terminal sacrifice, fewer females in the 500 and 1000 ppm groups had enlarged pituitary glands and subcutaneous masses (Table 5) . Pale foci/areas of the lung were seen in a greater number of females exposed to 1000 ppm styrene than in the other groups. Microscopically these were seen as foamy alveolar macrophages and/or cholesterol cleft granulomata. These lesions are occasionally seen as spontaneous findings in rats, and their presence, in low numbers, in this study was considered to be incidental. Histologically there was no increase in the number of tumorbearing rats in the treated groups compared to controls. In addition, there was no evidence that styrene exposure caused treatment-related increases in any tumor types in male or female rats (Table 6 ). There were treatment-related decreases in pituitary tumors and mammary tumors in females. The testes masses noted macroscopically were all interstitial cell adenomas; the incidences were 3.3, 3.3, 3.3, 7.4, and 11.5% of the rats for the 0, 50, 200, 500, and 1000 ppm groups, respectively. Testicular proliferative lesions were assessed using the current STP/ARP/AFIP criteria (McConnell et al., 1992) . Although the trend test was positive, the differences were judged to be incidental because (1) none of the incidences were significantly different from control by pairwise comparison, (2) the incidence in all groups was within the historical control range of 12 studies conducted in this strain of rats at this laboratory (0-13.5%), and (3) there was no treatmentrelated increase in nontumor findings typically associated with chemically induced interstitial cell tumors. Specifically, there was no increase in interstitial cell hyperplasia or seminiferous tubular atrophy.
In females, there were treatment-related decreases in pituitary tumors and mammary tumors. The incidences of adenocarcinomas of the pituitary were similar among exposed and control rats, but the incidences of adenomas decreased in a dose-related fashion. Fewer than 50% (24 of 49) of the females exposed to 1000 ppm styrene that survived for 2 years had pituitary adenomas, while 75% (21 of 28) of the control survivors had adenomas. Furthermore, the pituitary tumors in the females exposed to 1000 ppm styrene were smaller than those " SO/S, SO concentration/styrene concentration. * BLQ, below limit of quantitation; limit of quantitation for styrene, 100 ng/ml; and for SO = 10 ng/ml. in the controls. In 10 of 36 females exposed to 1000 ppm which developed pituitary tumors, the tumors were not observed at necropsy, while this was the case in only 2 of 51 control females with pituitary tumors. Similarly, fewer females exposed to styrene developed mammary adenocarcinomas than control rats. The incidences were 33, 22, 15, 8, and 3% of rats with adenocarcinomas for 0, 50, 200, 500, and 1000 ppm groups, respectively. Incidence of mammary adenocarcinoma was based on the total population in each group even though mammary tissue was not examined from the 50, 200, and 500 ppm females unless macroscopically abnormal (16, 17, and 22 rats, respectively) because mammary tumors are seldom found microscopically when not seen macroscopically. The incidence of mammary fibroadenomas was lower among styrene-exposed females than among control females, although there was no obvious dose response. Among survivors, the percentage of females with fibroadenomas was 38, 64, 58, 61, and 33% for groups exposed to 0, 50, 200, 500, and 1000 ppm, respectively. However, among females which died during the study, fewer of those exposed to styrene had fibroadenomas; the incidences were 52, 36, 29, 47, and 27%, respectively.
Nonneoplastic treatment-related histopathological findings in rats exposed for 52 or 104 weeks were confined to the olfactory epithelium of the nasal passages (Table 7) . The changes included atrophic and/or degenerative changes in the olfactory epithelium and changes in the underlying Bowman's glands compared to control rats (Fig. 2) . The atrophic/degenerative changes were classified as (1) focal disorganization with rosette formation (Figs. 3A, and 3B ), (2) atrophy/apparent cell loss where there was an apparent cell loss from the olfactory epithelium, but no decrease in the overall height of the epithelium (Figs. 3B and 3C) , and (3) atrophy/degeneration where there was a decrease in the height of the olfactory epithelium resulting from a decreased cellularity (Fig. 3E) . Prominent Bowman's glandular elements were present in the olfactory mucosa only in areas of atrophy with apparent cell loss (Fig. 3C) . Changes in the underlying Bowman's glands were not seen in rats exposed for 12 months, but were present in rats exposed for 24 months (Figs. 3D and 3E ). These changes comprised atrophy, which was generally confined to the glands in the dorsal median meatus; hypertrophy; hyperplasia; and dilatation. Hyperplasia of the basal cells in the olfactory epithelium was seen in rats killed after 12 months of exposure, but was not noted in older rats.
Other changes in the olfactory areas which occurred in only a few rats exposed for up to 24 months included ulceration, necrosis (Fig. 3F) , erosion, and epithelial hyperplasia/regenerative hyperplasia. Atrophy of the olfactory nerve fibers also was seen in occasional rats exposed to 500 or 1000 ppm styrene for up to 24 months. In rats exposed to 500 or 1000 ppm styrene, there was an increase in the degree of eosinophilic inclusions in the olfactory epithelium. The presence of eosinophilic inclusions is a common incidental finding in Sprague-Dawley rats (Monticello et al, 1990) .
The distribution of lesions was related to exposure concentration. In general, the lesions of rats exposed to styrene for 12 months were focal, whereas those in rats exposed for 24 months were more extensive. In rats exposed to 50 ppm for 12 months, lesions were seen only in the anterior areas of the dorsal median meatus and adjacent central septum (Fig. 4A) . After 24 months, the affected area was extended to include the median aspect of the dorsal leaflet of ethmoturbinate 3 (Fig.  4B) . As the dosage increased, the distribution of the lesions extended towards the most posterior ethmoturbinates. In rats exposed to 1000 ppm, all ethmoturbinates were affected (Figs. 5A and 5B). In rats exposed to 1000 ppm for 12 months, the lesions were focal, whereas after 24 months, the lesions were more extensive although unaffected portions of the olfactory epithelium were present.
DISCUSSION
Exposure to styrene by inhalation at concentrations up to 1000 ppm for 104 weeks resulted in decreased weight gain and changes in the olfactory epithelium in male and female CD (Sprague-Dawley) rats. In females, there were also increased survival and decreases in pituitary and mammary tumors. Seilkop (1995) reported that decreased body weight in female F344 rats was correlated with decreased incidence of pituitary and mammary tumors. While decreased weight may have had some effect on survival and tumor incidence in the present study, other factors seem to be involved. Females exposed to 500 and 1000 ppm had equally reduced body weight gains throughout the study; however, more females exposed to 1000 ppm survived (49 of 60) than those exposed to 500 ppm (40 of 60) and both groups had greater survival than those in the control group (29 of 60). In addition, only those exposed to 1000 ppm, not 500 ppm, had reduced incidence of pituitary tumors. Third, there was a dose-related decrease in mammary adenocarcinomas at all dose levels. It is not clear if Seilkop's correlations were based on mammary adenocarcinomas or on combining unrelated adenocarcinomas and fibroadenomas. In this study they were treated separately. Among styrene-treated females there was also a decrease in fibroadenomas compared to the control group, but there was no dose response. For body weight changes, the no observed adverse effect level (NOAEL) was 200 ppm. A NOAEL was not established for effects on the nasal epithelium since effects were seen at all exposure concentrations. Although there was little progression in the severity of the lesion between 1 year and 2 years of exposure, effects after 1 year of exposure were seen at lower concentrations than after 13 weeks (Cruzan et al., 1997) . In the 13-week study, lesions were seen in the olfactory epithelium of rats exposed to 500 ppm, but not in those exposed to 200 ppm. After 1 year of exposure to 200 ppm, there were lesions in the olfactory epithelium of males and females and in males exposed to 50 ppm. There was progression of the area affected with continued exposure; after 1 year the lesions were focal, but after 2 years more extensive areas were affected although portions of the ethmoturbinates were unaffected. The significance of these animal findings for human risk assessment is unclear since Odkvist et al. (1985) found no increase in nasal symptoms or histology score in 11 reinforced plastics workers exposed to 47-59 ppm styrene for 1 to 16 years compared to 25 referents.
This chronic study supports the lack of liver toxicity in rats from styrene exposure as demonstrated in the subchronic study (Cruzan et al., 1997) and other inhalation studies at similar exposure levels (Roycroft et al., 1992; Jersey et al., 1978) and disputes suggestions of liver toxicity in rats reported by Srivastava et al. (1982) and Vainio et al. (1979) . Ohashi et al. (1986) reported degenerative changes in the respiratory epithelium of the nasal septum and trachea of rats exposed to 150 or 1000 ppm styrene for 3 weeks. No such changes were found in either our thirteen week study (Cruzan et al., 1997) or in this study in rats exposed at levels of 50 to 1000 ppm for up to 2 years. Coccini et al. (1997) reported damage to trachea, type II and Clara cells in CRL-CD rats exposed to 300 ppm styrene 6 h/day 5 days/week for 2 weeks or by 3 daily intraperitoneal injections of 40 or 400 mg/kg. No such changes have been seen following exposure to styrene for 13 weeks at levels up to 1500 ppm (Cruzan et al., 1997) or up to 1000 ppm for up to 2 years in the present study. Coccini and co-workers did not indicate if they inflated the lungs with formalin. Failure to distend the lungs with fixative makes interpretation more difficult and may have contributed to the different results. Previous metabolic data of styrene in rats was obtained after a single exposure. The levels of styrene and SO were measured after an extended period of exposure (week 95) for comparison of metabolism after chronic exposure to previously published acute exposure and to assess whether saturation of metabolism had occurred at the highest exposure concentration. The blood levels of styrene were about as predicted by the Csanady et al. (1994) model up to 500 ppm, but at 1000 ppm were only half that predicted by the model. The blood styrene levels were very similar to values reported by Andersen et al. (1984) in Sprague-Dawley rats following a single 6-h exposure, but were up to 50% less than those reported following a single five hour exposure in Wistar rats (Withey and Collins, 1979) . While complete saturation of metabolism was not demonstrated in this study (i.e., the blood SO concentration continued to increase with each increasing exposure concentration), some 3 . Photomicrographs of nasal lesions in styrene-exposed rats. (A) Olfactory epithelium of the dorsal median meatus of a rat exposed at 1000 ppm for 1 year showing disorganization with rosette formation, H and E, X250. (B) Olfactory epithelium showing disorganization with rosette formation and atrophy with apparent cell loss in a rat exposed to 1000 ppm for 2 years, H and E, X250. (C) Atrophy with apparent cell loss from the olfactory epithelium. Prominent Bowman's glandular elements are present within the epithelium (-») in a rat exposed to 1000 ppm for 2 years, H and E, X250. (D) Olfactory epithelium showing atrophy with apparent cell loss and prominent Bowman's glandular elements within the epithelium in a rat exposed to 1000 ppm for 2 years. The submucosal Bowman's glands show dilatation (*) and hypertrophy (-»), H and E, X250. (E) Olfactory epithelium of the dorsal region of the central septum showing an extensive area of degeneration with decreased height of epithelium and atrophy of underlying Bowman's glands in a rat exposed to 1000 ppm for 2 years, H and E, X500. (F) Olfactory epithelium of the dorsal median meatus showing necrosis with exfoliation of the epithelium in a rat exposed at 1000 ppm for 2 years, H and E, X250. degree of saturation was shown. Over the range of 200 to 1000 ppm, the blood styrene concentration increased 12-fold in males, while blood SO concentration increased only 3-fold; in females blood styrene increased 15-fold, while blood SO increased 5-fold.
Although six chronic toxicity/oncogenicity studies were conducted on styrene in the 1970s and one in the early 1980s, none is fully acceptable under current standards. Some studies were deficient in design, some had problems with intercurrent disease, and none was conducted according to Good Laboratory Practices (McConnell and Swenberg, 1994) . Styrene was given by gavage, alone or as 70% mixture with /3-nitrostyrene, in four studies using Sprague-Dawley, Fischer 344 or BD IV rats at doses of 50 to 2000 mg/kg/day 5 days/week for 12 to 24 months (Table 1) . No treatment-related increases in tumors were reported. Styrene was given in the drinking water at 125 and 250 ppm for 2 years to Sprague-Dawley rats with no increases in tumor incidences. Conti et al. (1988) exposed groups of 30 male and 30 female Sprague-Dawley rats to 25, 50, 100, 200, or 300 ppm styrene 4 h/day 5 days/week for 52 weeks during [1974] [1975] , with observation for an additional 52 weeks. They reported total mammary tumor incidences of 57, 80, 70, 77, 80 , and 83%, respectively, and malignant mammary tumor incidences of 10, 20, 13, 15, 40, and 30%, respectively. Even though there is no obvious dose response in these data, the authors concluded the increased mammary tumors were styrene-related. Although the historical control incidence for this laboratory was not given in the paper, Dr. Maltoni (1978) had previously written, "It should be pointed out that the incidence of mammary tumors is quite high in the colony of rats we employ, that some fluctuation of that incidence is currently observed from group to group, and that the results of the other experiments do not support a correlation between styrene exposure and mammary tumors." It has also been pointed out by others that the frequency of spontaneously developing mammary tumors is high in female Sprague-Dawley rats (van Zwieten et al., 1994) . In another inhalation study (Jersey et al., 1978) , the authors concluded that styrene did not cause increased mammary tumors in female Sprague-Dawley rats exposed to 600 or 1000 ppm styrene for 89 weeks and observed until 104 weeks. In that study, females exposed to 600 ppm had a greater incidence of malignant mammary tumors (8%) than the concurrent controls (1%), but not greater than historical controls (mean, 6%; range, 0-9%). In addition, females exposed to 1000 ppm did not have an increased incidence of malignant mammary tumors (0%). There was also no increase in mammary fibroadenomas (71, 75, and 74%, respectively) .
When all the groups of female rats in these eight studies exposed to styrene are analyzed by cumulative lifetime dose (Table 8) , there is no indication of a dose response for increased mammary tumors. In fact, it is only the lowest exposures tested, and all in the same study, that report increased mammary tumors.
Exposure to styrene has not been associated with treatmentrelated increased incidences of tumors at any other sites in rats. Based on an overall evaluation of eight chronic/oncogenicity studies, there is clear evidence that styrene does not induce cancer in rats. 
